Chronic kidney disease affects more than 850 million people worldwide, yet treatment options remain limited, especially for rare and inherited forms of the disease. These conditions, driven by pathogenic variants in single genes, are often poorly represented in research databases, making therapeutic discovery and patient recruitment exceptionally difficult. Now, advances in clinicogenomic data integration are beginning to close that gap.
This compendium — comprising an expert Q&A article, an infographic, and a recorded webinar — examines how large-scale genomic and clinical datasets are accelerating discovery across the full drug development continuum, from early target identification through clinical trial execution.
Download this compendium to learn:
- How clinicogenomic research is expanding understanding of rare kidney disease biology
- Why longitudinal real-world data is becoming increasingly important in precision medicine research
- How integrated datasets may support future advances in targeted therapies and translational medicine
